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Objectives: Staphylococcus epidermidis is now among the most important pathogenic 
agents responsible for bloodstream nosocomial infections and for biofilm formation on 
indwelling medical devices. Its increasing resistance to common antibiotics is a challenge for 
the development of new antimicrobial agents. Accordingly, the goal of this study was to 
evaluate the effect of farnesol, a natural sesquiterpenoid, on Staphylococcus epidermidis 
biofilm cells and compare this one with the effect of vancomycin, one of the most frequently 
used antibiotics to treat resistant nosocomial infections. Another aim of this work was to 
determine if subjecting S. epidermidis cells to farnesol they acquire resistance. 
Methods: A 24 h kinetic study was performed using vancomycin at the peak serum concentration 
(40mg/L) and farnesol at concentrations of 30, 100, 200 and 300 microM. The growth inhibition 
effect of farnesol and vancomycin on biofilm cells of S. epidermidis was assessed by XTT 
(the reduction of this tetrazolium salt is a measure of cellular activity and is easily assessed 
by colorimetry) and Crystal Violet, which measures total biomass of biofilm. The biofilm 
cells were analysed by confocal laser scanning microscopy after being stained with 
Live/Dead. Resistance to farnesol and vancomycin was tested growing S. epidermidis 
planktonic cells in sub-inhibitory concentrations of farnesol and vancomycin and then 
subjecting these cells to inhibitory concentrations of both antimicrobial agents during 24 
hours. After that, cellular activity was assessed by XTT. This was repeated for 5 consecutive 
  
days. 
Results: Both tested agents act at the cell wall level, vancomycin inhibits the biosynthesis of 
bacterial cell wall, while farnesol is considered to disrupt the normal barrier function of the 
cell membrane. Interestingly, farnesol at a concentration higher than 200 microM displayed 
the same or higher effectiveness of vancomycin at peak serum concentration. In fact, the 
response of the strains tested was very similar for both farnesol (>200 microM) and 
vancomycin. Regarding cells resistance to farnesol, the results point out to a slight increase 
of tolerance but not to an acquired resistance, because the percentage of inhibition was 
steady along the time. 
Conclusions: Overall, the results indicate a potential antibacterial effect of farnesol against 
S. epidermidis, and therefore the possible action of this molecule on the prevention of S. 
epidermidis related infections. 
 
 
